On July 24, 2014, Organovo Holdings, Inc. (the "Company") announced that it has entered into an agreement with Janssen Research and Development (JRD), a pharmaceutical company of Johnson & Johnson, to evaluate the use of 3D bio-printed tissue in a drug discovery setting, outside of the Company's work in 3D liver tissue for toxicity testing. Terms have not been disclosed.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.